Notice of Closed Meeting, 730 [2019-00274]
Download as PDF
amozie on DSK3GDR082PROD with NOTICES1
730
Federal Register / Vol. 84, No. 21 / Thursday, January 31, 2019 / Notices
costs to mount responses in the event of
an importation of a dog with CRVV. In
addition, individuals or their insurance
companies may face costs associated
with post-exposure prophylaxis if they
are exposed to the imported dog.
A threshold analysis was performed
to compare the potential annualized
costs and benefits of the clarification to
the guidance to the potential cost of an
importation of a dog with CRVV. To
perform the threshold analysis, HHS/
CDC compared the most likely estimate,
lower bound, and upper bound of the
annual net benefits (reduced costs) of
the new guidance to the potential costs
of an importation and calculated the
annual risk of importation necessary for
costs to equal benefits (reduced costs).
HHS/CDC rabies subject matter
experts estimate that the public health
response would require about 800 hours
per event for investigation, providing
post-exposure prophylaxis to about 16
people exposed to the infected dog after
importation, and addressing 30 animal
exposures per importation. The net
benefits (reduced costs) estimate can be
compared to the estimated response
costs associated with a dog imported
while infected with CRVV ($213,833,
range $171,066 to $256,599). See
Section 7 of the supplemental appendix
for additional details on this cost
estimate. This response cost does not
include the small risk that a person
could die after becoming infected with
the rabies virus in the absence of
receiving post-exposure prophylaxis.
Although U.S. residents have died after
exposure to rabid dogs in other
countries, no such deaths have resulted
from exposures to U.S. dogs since CRVV
was eliminated in the United States in
2007. The probability of such a death
cannot be quantified, but is expected to
be very low under either scenario.
Expected net benefits (reduced costs)
would exceed the potential costs
associated with the importation of a dog
with CRVV if fewer than 26 dogs per
year with CRVV are imported from
countries classified as CRVV-free or
low-risk under the new guidance using
the most likely estimates. In the worst
case scenario, the lower bound estimate
of annualized benefits (reduced costs,
$2.6 million) minus the upper bound
estimate of annualized costs ($780,000)
results in an annualized net benefit of
about $1.8 million. This worst case
annualized net benefit can be compared
to the upper bound cost estimate
associated with the importation of a dog
with CRVV ($256,599 per event) to
estimate a worst case scenario threshold
(6.9 dogs per year).
This threshold analysis can be
compared to surveillance data from
VerDate Sep<11>2014
20:21 Jan 30, 2019
Jkt 247001
Mexico, a country that is considered
low-risk. Mexico only identified 11 dogs
over the previous 2 years in which
surveillance data were available.10
Thus, even if all of the dogs found with
CRVV in Mexico over the past two years
had been imported to the United States,
the response costs would have fallen
under the threshold result. Even in the
worst case scenario, it is extremely
unlikely that costs will exceed benefits
as a result of this clarification in
guidance. As noted above, HHS/CDC
also believes that any increased risk of
importation from a CRVV-free or lowrisk country may be offset by allowing
DHS/CBP officers to spend more time
evaluating dogs entering the United
States from high-risk countries. DHS/
CBP officers reported that they expected
to increase the amount of time spent on
dogs from high-risk countries by 3–17
minutes per dog under the new
guidance. By refocusing screening effort
at U.S. POEs from dogs from CRVV-free
or low-risk countries to dogs from highrisk countries, the overall risk of
importation of a dog with CRVV may be
reduced.
Possible Additional Activities by State
or Local Governments
As noted throughout this FRN,
importers should continue to check
with state and local government officials
regarding requirements of the final
destination prior to entry or re-entry
into the United States; this new federal
policy is not intended to invalidate or
supersede such requirements. State and
local governments may also have to
increase efforts to educate their
populations about their dog vaccination
requirements in the absence of the HHS/
CDC requirement for proof of rabies
vaccination for dogs to enter from
CRVV-free or low-risk countries under
the previous guidance. However, HHS/
CDC was not able to estimate any costs
associated with these efforts.
V. Paperwork Reduction Act
This clarification does not institute a
new collection of information. The
collection of information, has been
previously approved by the Office of
Management and Budget (OMB) in
accordance with the requirements of the
Paperwork Reduction Act (44 U.S.C.
3507) and assigned the following OMB
control number: Foreign Quarantine:
OMB Control No. 0920–0134, expiration
date 5/31/2019.
10 Ma, X., et al. (2018). ‘‘Rabies surveillance in the
United States during 2016.’’ JAVMA 252(8): 945–
957.
PO 00000
Frm 00085
Fmt 4703
Sfmt 9990
Dated: January 28, 2019.
Sandra Cashman,
Executive Secretary, Centers for Disease
Control and Prevention.
[FR Doc. 2019–00506 Filed 1–30–19; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended, and the Determination of
the Chief Operating Officer, CDC,
pursuant to Public Law 92–463. The
grant applications and the discussions
could disclose confidential trade secrets
or commercial property such as
patentable material, and personal
information concerning individuals
associated with the grant applications,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Disease, Disability,
and Injury Prevention and Control Special
Emphasis Panel (SEP)—Funding Opportunity
Announcement (FOA), PAR 16–098,
Cooperative Research Agreements to the
World Trade Center Health Program (U01).
Dates and Times: March 27, 2019, 8:00
a.m.–5:00 p.m., EDT and March 28, 2019,
8:00 a.m.–12:00 p.m., EDT.
Place: Hampton Inn & Suites Atlanta
Buckhead, 3312 Piedmont Road, Atlanta,
Georgia 30305, Telephone: (404) 816–7309.
Agenda: To review and evaluate grant
applications.
For Further Information Contact: Nina
Turner, Ph.D., Scientific Review Officer,
CDC/NIOSH, 1095 Willowdale Road,
Mailstop L10555, Morgantown, West Virginia
26505, (304) 285–5975, nxt2@cdc.gov.
The Chief Operating Officer, Centers for
Disease Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for both
the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Sherri A. Berger,
Chief Operating Officer, Centers for Disease
Control and Prevention.
[FR Doc. 2019–00274 Filed 1–30–19; 8:45 am]
BILLING CODE 4163–18–P
E:\FR\FM\31JAN1.SGM
31JAN1
Agencies
[Federal Register Volume 84, Number 21 (Thursday, January 31, 2019)]
[Notices]
[Page 730]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-00274]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended, and the Determination of the Chief Operating
Officer, CDC, pursuant to Public Law 92-463. The grant applications and
the discussions could disclose confidential trade secrets or commercial
property such as patentable material, and personal information
concerning individuals associated with the grant applications, the
disclosure of which would constitute a clearly unwarranted invasion of
personal privacy.
Name of Committee: Disease, Disability, and Injury Prevention
and Control Special Emphasis Panel (SEP)--Funding Opportunity
Announcement (FOA), PAR 16-098, Cooperative Research Agreements to
the World Trade Center Health Program (U01).
Dates and Times: March 27, 2019, 8:00 a.m.-5:00 p.m., EDT and
March 28, 2019, 8:00 a.m.-12:00 p.m., EDT.
Place: Hampton Inn & Suites Atlanta Buckhead, 3312 Piedmont
Road, Atlanta, Georgia 30305, Telephone: (404) 816-7309.
Agenda: To review and evaluate grant applications.
For Further Information Contact: Nina Turner, Ph.D., Scientific
Review Officer, CDC/NIOSH, 1095 Willowdale Road, Mailstop L10555,
Morgantown, West Virginia 26505, (304) 285-5975, nxt2@cdc.gov.
The Chief Operating Officer, Centers for Disease Control and
Prevention, has been delegated the authority to sign Federal
Register notices pertaining to announcements of meetings and other
committee management activities, for both the Centers for Disease
Control and Prevention and the Agency for Toxic Substances and
Disease Registry.
Sherri A. Berger,
Chief Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2019-00274 Filed 1-30-19; 8:45 am]
BILLING CODE 4163-18-P